STWA, Inc. (OTCBB: ZERO) reached up 29.85% in morning trading to $.87 with 1M shares traded. STWA, Inc. develops and commercializes energy efficiency technologies that assist in meeting increasing global energy demands, improving the economics of oil extraction and transport, and reducing greenhouse gas emissions. The Company's intellectual property portfolio includes 24 domestic and international patents and patents pending, which have been developed in conjunction with and exclusively licensed from Temple University. STWA's technologies include Applied Oil Technology™ (AOT™) which is designed to improve oil flow through pipelines. AOT™ has been proven in U.S. Department of Energy tests to increase the energy efficiency of oil pipeline pump stations. ELEKTRA™ improves diesel engine efficiency for industrial diesel engines, as well as diesel-powered trucks, trains, marine vessels, military fleets and jet turbines. STWA, Inc. (OTCBB: ZERO) announced that both matters put to vote, the election of Cecil Bond Kyte, Charles Blum and Nathan Shelton as directors, and the appointment of Weinberg & Co. as the Company's independent auditor for the fiscal year ending December 31, 2012, were approved by shareholders at its annual shareholders meeting which took place on Friday, September 21, 2012.
Mimvi, Inc. (OTCQB: MIMV) reached up 14.91% in morning trading to $.655 with 2M shares traded. MIMVI, Inc. is a pure-play search and recommendation technology company. Its proprietary search and "intelligent" recommendation algorithms enable the search and discovery of Mobile Apps, Mobile Content and Mobile Products across multiple devices and platforms, including: Apple's iPhone and iPad, Google Android, BlackBerry, Windows Phone, Facebook and Web Apps. Mimvi, Inc. (MIMV) has announced that it has finalized a partnership agreement with Microsoft Corp. The partnership will see Mimvi develop a number of products and services to complement Microsoft's Windows Azure and Windows Mobile 8 Platforms. The agreement also involves Microsoft making investments in Mimvi in the form of engineering services, software, and cash.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) reached up 9.09% in morning trading to $.54 with 300K shares traded. Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled “5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents.”
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
